Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study
Authors:
- V. I. MazurovVMV. I. Mazurov
- E. G. ZotkinEZE. G. Zotkin
- I. Z. GaydukovaIGI. Z. Gaydukova
- E. P. IlivanovaEIE. P. Ilivanova
- T. V. PlaksinaTPT. V. Plaksina
- O. B. NesmeyanovaONO. B. Nesmeyanova
- N. F. SorokaNSN. F. Soroka
- E. A. KunderEKE. A. Kunder
- E. A. DokukinaEDE. A. Dokukina
- Yu. N. LinkovaYLYu. N. Linkova
- N. A. KravtsovaNKN. A. Kravtsova
Open Access
- 13 May 2021
- journal article
- research article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (2) , 141-151-151
Abstract
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX) resistant patients with active rheumatoid arthritis (RA).Materials and methods. 105 patients with active RA were randomized in a 1:1:1 ratio into two LVL or placebo groups. LVL was administered subcutaneously at a dose of 162 mg every week (QW) or every other week (Q2W). All patients received MTX. After evaluating the primary endpoint of 20% improvement in ACR criteria (ACR20) at week 12, patients in the placebo group were switched to LVL Q2W. The study duration was 56 weeks. The frequency, profile, degree and severity of adverse events were determined in each group for safety assessment. The immunogenicity of LVL was determined by the proportion of patients with identified binding and neutralizing antidrug antibodies. Results. LVL in both regimens was superior to placebo. At week 12, the incidence of ACR20 achievement was 77.1% (LVL QW), 57.1% (LVL Q2W), and 17.1% (placebo) with 95% confidence intervals [37.53; 82.54] (pConclusion. In MTX-resistant patients with active RA, the efficacy of both LVL regimens at a dose of 162 mg in combination with MTX was significantly superior to MT monotherapy. LVL QW lead to highest treatment response. LVL has been shown to be well tolerated and low immunogenicity. LVL safety profile is similar to IL6R inhibitors.Keywords
This publication has 17 references indexed in Scilit:
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases, 2020
- Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocolRheumatology, 2018
- SAT0040 Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-il-6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteersAnnals of the Rheumatic Diseases, 2018
- Rheumatoid arthritisNature Reviews Disease Primers, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyArthritis & Rheumatology, 2015
- Test–retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen jointsClinical Rheumatology, 2013
- The new ACR/EULAR remission criteria: rationale for developing new criteria for remissionRheumatology, 2012
- Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics registerArthritis Research & Therapy, 2006
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995